Cargando…
1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
BACKGROUND: Vancomycin induces exposure-related acute kidney injury [AKI]; yet the toxicodynamic (TD) driver for toxicity (area under the curve [AUC], vs. maximum concentration [CMAX] vs. trough concentrations [CMIN]) remains unclear. Recent vancomycin guidelines now recommend monitoring AUC over tr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809992/ http://dx.doi.org/10.1093/ofid/ofz360.1432 |
_version_ | 1783462137514950656 |
---|---|
author | Avedissian, Sean N Pais, Gwendolyn M Liu, Jiajun O’Donnell, J Nicholas Lodise, Thomas Prozialeck, Walter Lamar, Peter Neely, Michael Scheetz, Marc H |
author_facet | Avedissian, Sean N Pais, Gwendolyn M Liu, Jiajun O’Donnell, J Nicholas Lodise, Thomas Prozialeck, Walter Lamar, Peter Neely, Michael Scheetz, Marc H |
author_sort | Avedissian, Sean N |
collection | PubMed |
description | BACKGROUND: Vancomycin induces exposure-related acute kidney injury [AKI]; yet the toxicodynamic (TD) driver for toxicity (area under the curve [AUC], vs. maximum concentration [CMAX] vs. trough concentrations [CMIN]) remains unclear. Recent vancomycin guidelines now recommend monitoring AUC over troughs. Here we employed our translational rat model with intensive dose fractionation and sensitive FDA qualified urinary biomarkers to better understand TD relationship. METHODS: Male Sprague-Dawley rats received intravenous (IV) vancomycin via an internal jugular vein catheter. Total daily doses of 300 and 400 mg/kg/day were administered as a single, twice, thrice and four times a day injection over 24 hours. Controls received IV saline. Plasma sampling was conducted via a second dedicated jugular catheter, with up to 8 samples in 24 hours. Twenty-four-hour urine was collected during this time and assayed for kidney injury molecule 1 (KIM-1) and other urinary biomarkers using the MILLIPLEX MAP Rat Kidney Panel. Vancomycin in plasma was quantified via LC-MS/MS. PK analyses were conducted using Pmetrics for R. PK exposures during the first 24 hours (i.e., AUC(0-24hours), CMAX(0-24hours)) were calculated from Bayesian posteriors. Pharmacokinetic-toxicodynamic (PK-TD) relationships were assessed with the best fit mathematic model (e.g., exposure-response curve fitting in GraphPad v.7). RESULTS: Sixty-four vancomycin treated and control rats contributed to PK-TD data. An exposure-response (via 4-parameter Hill) model was identified for AUC(0-24hours)vs KIM-1 (R(2) = 0.62, Figure 1a). Convergence was not obtained for exposure-response models for CMAX(0-24hours) and CMIN, which was also verified visually (Figure 1b and c). Despite the intensive fractionation, AUC(0-24hours)and CMAX(0-24hours) were highly correlated (P < 0.001, rho = 0.89) and this correlation was consistent across KIM-1 values (Figure 2). CONCLUSION: Vancomycin-induced kidney injury was driven by AUC(0-24 hours) and not CMIN. Continuous infusion studies are needed to understand if changing the infusion profile can improve safety; however, these studies suggest that isometric AUCs may result in similar toxicity. When using intermittent infusion schemes, clinicians should focus on AUC to prevent AKI. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6809992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68099922019-10-28 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury Avedissian, Sean N Pais, Gwendolyn M Liu, Jiajun O’Donnell, J Nicholas Lodise, Thomas Prozialeck, Walter Lamar, Peter Neely, Michael Scheetz, Marc H Open Forum Infect Dis Abstracts BACKGROUND: Vancomycin induces exposure-related acute kidney injury [AKI]; yet the toxicodynamic (TD) driver for toxicity (area under the curve [AUC], vs. maximum concentration [CMAX] vs. trough concentrations [CMIN]) remains unclear. Recent vancomycin guidelines now recommend monitoring AUC over troughs. Here we employed our translational rat model with intensive dose fractionation and sensitive FDA qualified urinary biomarkers to better understand TD relationship. METHODS: Male Sprague-Dawley rats received intravenous (IV) vancomycin via an internal jugular vein catheter. Total daily doses of 300 and 400 mg/kg/day were administered as a single, twice, thrice and four times a day injection over 24 hours. Controls received IV saline. Plasma sampling was conducted via a second dedicated jugular catheter, with up to 8 samples in 24 hours. Twenty-four-hour urine was collected during this time and assayed for kidney injury molecule 1 (KIM-1) and other urinary biomarkers using the MILLIPLEX MAP Rat Kidney Panel. Vancomycin in plasma was quantified via LC-MS/MS. PK analyses were conducted using Pmetrics for R. PK exposures during the first 24 hours (i.e., AUC(0-24hours), CMAX(0-24hours)) were calculated from Bayesian posteriors. Pharmacokinetic-toxicodynamic (PK-TD) relationships were assessed with the best fit mathematic model (e.g., exposure-response curve fitting in GraphPad v.7). RESULTS: Sixty-four vancomycin treated and control rats contributed to PK-TD data. An exposure-response (via 4-parameter Hill) model was identified for AUC(0-24hours)vs KIM-1 (R(2) = 0.62, Figure 1a). Convergence was not obtained for exposure-response models for CMAX(0-24hours) and CMIN, which was also verified visually (Figure 1b and c). Despite the intensive fractionation, AUC(0-24hours)and CMAX(0-24hours) were highly correlated (P < 0.001, rho = 0.89) and this correlation was consistent across KIM-1 values (Figure 2). CONCLUSION: Vancomycin-induced kidney injury was driven by AUC(0-24 hours) and not CMIN. Continuous infusion studies are needed to understand if changing the infusion profile can improve safety; however, these studies suggest that isometric AUCs may result in similar toxicity. When using intermittent infusion schemes, clinicians should focus on AUC to prevent AKI. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809992/ http://dx.doi.org/10.1093/ofid/ofz360.1432 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Avedissian, Sean N Pais, Gwendolyn M Liu, Jiajun O’Donnell, J Nicholas Lodise, Thomas Prozialeck, Walter Lamar, Peter Neely, Michael Scheetz, Marc H 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury |
title | 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury |
title_full | 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury |
title_fullStr | 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury |
title_full_unstemmed | 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury |
title_short | 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury |
title_sort | 1568. the pharmacodynamic–toxicodynamic relationship of auc and cmax in vancomycin-induced kidney injury |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809992/ http://dx.doi.org/10.1093/ofid/ofz360.1432 |
work_keys_str_mv | AT avedissianseann 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT paisgwendolynm 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT liujiajun 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT odonnelljnicholas 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT lodisethomas 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT prozialeckwalter 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT lamarpeter 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT neelymichael 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury AT scheetzmarch 1568thepharmacodynamictoxicodynamicrelationshipofaucandcmaxinvancomycininducedkidneyinjury |